Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc BIIB posted Q4 sales of 2.73 billion, beating the consensus of $2.62 billion, down 4.2% Y/Y. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus

The shares of Biogen Inc (NASDAQ:BIIB) are down 5% to trade at $213.70 at last check, as the company's bleak 2022 forecast weighs.

Biogen Stock Hits 5-Year Low After Weak Forecast

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 2.11% and 4.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates

Biogen Inc BIIB is trading lower Thursday morning after the company announced worse-than-expected fourth-quarter earnings results and issued guidance below estimates. Biogen reported quarterly revenue of $2.73 billion, which beat the estimate of $2.62 billion.

Why Biogen Shares Are Sliding Today

Shares of Biogen Inc. BIIB, -1.92% were down 3.7% in premarket trading on Thursday after missing earnings and revenue expectations in the final quarter of 2021. Biogen had earnings of $368.2 million, or $2.51 per share, in the fourth quarter of 2021, compared with $357.9 million, or $2.33 per share, in the fourth quarter a year ago.

Biogen's stock falls 3.7% on earnings miss, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter

Biogen Inc on Thursday forecast 2022 adjusted earnings well below analysts' estimates, as it expects minimal sales from its Alzheimer's drug following the U.S. Medicare regulator's move to limit coverage of the treatment.

Biogen 2022 profit forecast misses estimates on Aduhelm woes

Biogen Inc BIIB has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody for B-cell non-Hodgkin's lymphoma (NHL), including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).  [LIVE NOW ON YOUTUBE] Click Here to Watch a FREE MASTERCLASS on the Ultimate Bear Market Survival Guide with Matt Maley!

Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab

CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it exercised its option to participate in the development and commercialization of mosunetuzumab. Biogen will pay a $30 million one-time option fee to Genentech, a member of the Roche Group, as part of the companies' long-standing collaboration on antibodies targeting CD20.

Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody

Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports fourth-quarter results.

Is a Beat Likely for Biogen (BIIB) This Earnings Season?

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nancy Leaming and Brian Posner will retire from Biogen's Board of Directors, effective at the time of the Company's 2022 annual meeting of stockholders.

Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors

Alibaba

These stocks aren't safe, but they have the potential to generate some great returns in the long run.

Got $10,000? These 2 Growth Stocks Are Trading Near Their 5-Year Lows

Biogen (BIIB) is selling its equity stake in the Samsung Bioepis joint venture to partner Samsung Biologics

Biogen (BIIB) to Sell Biosimilar JV Stake to Samsung Biologics

Biogen Inc. ( BIIB , Financial) announced on Thursday that it has entered into an agreement that will see Samsung BioLogics ( XKRX:207940 , Financial) acquire Biogen's equity stake in the Samsung Bioepis joint venture for an aggregate consideration of up to $2.3 billion. The cash injection should help Biogen reach important research goals, such as the next phase in clinical trials for its controversial Alzheimer's treamtent, Aduhelm.

Biogen Announces Cash Injection, Moves Forward With Alzheimer's Trials

Biogen will be selling its stake in a biosimilars joint venture to partner Samsung Biologics for up to $2.3 billion.

Biogen Sells Stake in Biosimilars Venture for $2.3 Billion

Biogen Inc. BIIB, -0.30% shares jumped in after-hours trading Thursday following an announcement that it is selling its part of a joint venture to Samsung Electronics Co. Ltd. 005930, -2.73% Biogen has been working with Samsung Bioepis since 2012, according to a news release, and will sell its equity stake in the bio-similars venture to the Samsung parent company for $2.3 billion.

Biogen stock pops after agreement to sell Samsung part of joint venture

Agreement with Biogen to buyout Biogen's (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USD $2.3 billion Transaction projected to be accretive to earnings in 2022 and thereafter, fully capitalizing on the high growth potential of Samsung Bioepis Expected to accelerate growth in biosimilars and novel therapeutics R&D Purchase to be funded through a portion of KRW 3 trillion paid-in capital increase, focused on investment in Samsung Biologics' future growth INCHEON, South Korea, Jan. 27, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced today that it has reached an agreement with Biogen for the buyout of Biogen's stake in the Samsung Bioepis joint venture for USD $2.3 billion. The transaction is expected to boost earnings growth of Samsung Biologics on a consolidated basis, fully capitalizing on Samsung Bioepis' growth outlook.

Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis

The companies will continue with their exclusive agreements, including for commercialization of their current portfolio The companies will continue with their exclusive agreements, including for commercialization of their current portfolio

Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion

Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Biogen Inc. (BIIB) Q4 Earnings Expected to Decline

CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer's disease, including details of the study's goal for diverse enrollment and primary endpoint.

Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®

The company is still dealing with the fallout of a controversial regulatory approval.

Is Biogen a Buy?

The Centers for Medicare and Medicaid may ensure the commercial death of Biogen's controversial Alzheimer's drug. And that leads at least one analyst to wonder if more radical steps need to be taken.

Biogen After the Alzheimer's Drug Debacle: Time to Sell the Parts?

Is Biogen a Buy After the Latest Aduhelm Disaster?

Biogen Inc. (BIIB) closed at $239.30 in the latest trading session, marking a +1.11% move from the prior day.

Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know

As the prospects for its once-promising Alzheimer's drug continue to dim, Biogen Inc. ( BIIB , Financial) is reportedly exploring strategic options, including selling itself or acquiring a smaller bioscience company. The Boston-area biotech has gone so far as to hire Goldman Sachs Group Inc. ( GS , Financial) to put together a roster of potential acquisition targets, Stat reports, citing a person familiar with the companies' relationships.

Biogen Is More Likely to Be a Buyer Than Seller

Biogen Inc is working with investment bank Goldman Sachs to find potential targets for acquisitions, Stat News reported on Thursday, citing an unnamed source.

News for Biogen Stock (BIIB)